PSORIASIS
Global Burden of Disease
Psoriasis is a chronic, non-contagious, painful, and disabling disease with no cure and which has a significant negative impact on patients’ quality of life (QoL). It can occur at any age but is most common in the age group 50–69.
125 million people worldwide or 2-4 percent of the total population have psoriasis, according to the World Psoriasis Day consortium with over 85% of patients receiving treatment using topical drugs. According to the National Psoriasis Foundation (NPF), between 70% and 90% of psoriasis patients suffer from itching with itching, flaking and scaling reported to be the most burdensome symptom to patients. People living with psoriatic disease are also at an elevated risk of developing other chronic and serious health conditions, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.
Current treatment options include topicals, orals and biologics (depending on severity) and whether Psoriatic Arthritis (PSA) is present. According to the NPF, psoriasis is defined as Mild (<3% body surface area “BSA” covered), Moderate (3%-10% BSA), or Severe (>10% BSA). Approximately 80% of patients with psoriasis can sufficiently be treated with topical therapies due as the disease is localized to skin issues. Most patients on systemic therapies also use topicals for spot treatment.
The total cost of psoriasis in the US is estimated to be around $35.2 billion, with $12.2 billion in incremental medical costs.
Unmet Need
For many reasons, psoriasis can be psychologically devastating. Patients’ lives become especially difficult when psoriasis is present in highly visible areas of the skin such as the face and hands.
Surveys show that patients need therapies that quickly and effectively reduce the plaque and itch (within 7 applications) and can be easily used in daily routines. Poor adherence has historically been a major problem for topical treatments, resulting in suboptimal treatment effect in a real-world settings. The main reason for this is that most potent topicals that are suitable for long term use are greasy or difficult to apply.
To address this unmet need, MC2 Therapeutics developed Wynzora® Cream, a cream-based fixed dose combination of calcipotriene (“CAL”) and betamethasone dipropionate (“BDP”) for topical treatment of plaque psoriasis, including scalp psoriasis in adults. Its dual mode of action of CAL and BDP provides fast onset and high efficacy through targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product with a favourable safety profile. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, which allows for a convenient-to-use aqueous cream formulation that releases the full potential of the actives.
Psoriasis Treatment guidelines:
For further information on selected treatment guidelines, please visit the below links:
MC2 Therapeutics is a proud partner of the National Psoriasis Foundation (NPF). Please visit their website below for more information on psoriasis:
